Severe leukopenia associated with mild hepatotoxicity in an HIV carrier treated with nevirapine.
Nevirapine is a non-nucleoside reverse transcriptase inhibitor used in the treatment of human immunodeficiency virus (HIV)-infected patients and in post-exposure prophylaxis. However, its use has recently been limited because of adverse cutaneous and hepatic effects. We report an HIV-infected woman who developed mild leukopenia as the first sign of a nevirapine-related adverse event, which was followed by skin and hepatic toxicity associated with a more severe leukopenia.
Shahar
Eduardo
E
Institute of Allergy, Clinical Immunology and AIDS, Rambam Medical Center, 31096 Haifa, Israel. ed_shahar@rambam.health.gov.il
Krivoy
Norberto
N
Weltfriend
Sara
S
Pollack
Shimon
S
D000328:Adult; D019380:Anti-HIV Agents / Q000009:adverse effects* / Q000627:therapeutic use; D056486:Chemical and Drug Induced Liver Injury; D005260:Female; D015658:HIV Infections / Q000188:drug therapy*; D006801:Humans; D007970:Leukopenia / Q000139:chemically induced*; D019829:Nevirapine / Q000009:adverse effects* / Q000627:therapeutic use
D019380:Anti-HIV Agents; D019829:Nevirapine